SUPERNUS PHARMACEUTICALS, INC.(SUPN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,037 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SUPN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for SUPERNUS PHARMACEUTICALS, INC. (SUPN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 41.9/100 on a 32-signal composite quality model, placing it at rank #2,037 of 2,962 stocks — the bottom half of the AI-ranked universe. SUPN scores in the top quartile across revenue growth (76.4). Areas of concern include profitability (16.6) and balance sheet strength (19.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $219.1M, net income of $-58.4M, free cash flow of $-5.4M. Top institutional holders of SUPN by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR. SUPERNUS PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 36 and 71 since 2021, currently 41.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$219.1M
Net Income
Q2 2026
$-58.4M
Free Cash Flow
Q2 2026
$-5.4M
ROIC
Q2 2026
-22.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+8.6% YoYNet Income
-152.2% YoYOperating Income
-176.3% YoYEPS (Diluted)
-151.5% YoYTotal Assets
+6.2% YoYTotal Debt
Op. Cash Flow
-72.5% YoYFree Cash Flow
-73.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $719.0M +8.6% | $661.8M +8.9% | $607.5M -8.9% | $667.2M +15.1% | $579.8M +11.4% | $520.4M |
| Net Income | $-38.5M -152.2% | $73.9M +5512.8% | $1.3M -97.8% | $60.7M +13.6% | $53.4M -57.9% | $127.0M |
| Operating Income | $-62.3M -176.3% | $81.7M +1649.9% | $-5.3M -111.4% | $46.1M -46.4% | $86.0M -50.5% | $173.7M |
| EPS (Diluted) | $-0.68 -151.5% | $1.32 +6500.0% | $0.02 -98.1% | $1.04 +6.1% | $0.98 -58.5% | $2.36 |
| Total Assets | $1.45B +6.2% | $1.37B +7.1% | $1.28B -25.0% | $1.70B +0.8% | $1.69B +12.3% | $1.50B |
| Total Debt | — | — | — | — | $379.3M | — |
| Operating Cash Flow | $47.3M -72.5% | $172.0M +54.8% | $111.1M -4.9% | $116.8M -8.1% | $127.1M -8.1% | $138.4M |
| Free Cash Flow | $46.0M -73.1% | $171.2M +54.9% | $110.5M -5.1% | $116.4M | — | $134.9M |
Get alerted when SUPN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SUPERNUS PHARMACEUTICALS, INC. including:
Top Institutional Holders of SUPN
BlackRock, Inc.
$434.9M9,350,046 shMILLENNIUM MANAGEMENT LLC
$179.2M3,853,212 shVANGUARD PORTFOLIO MANAGEMENT LLC
$153.7M3,305,429 shARMISTICE CAPITAL, LLC
$123.1M2,646,201 shVANGUARD CAPITAL MANAGEMENT LLC
$117.1M2,516,721 shSTATE STREET CORP
$114.4M2,459,828 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$110.6M2,378,329 shDIMENSIONAL FUND ADVISORS LP
$96.7M2,078,090 shGEODE CAPITAL MANAGEMENT, LLC
$73.0M1,570,088 shStephens Investment Management Group LLC
$69.1M1,485,821 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $434.9M | 9,350,046 |
| MILLENNIUM MANAGEMENT LLC | $179.2M | 3,853,212 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $153.7M | 3,305,429 |
| ARMISTICE CAPITAL, LLC | $123.1M | 2,646,201 |
| VANGUARD CAPITAL MANAGEMENT LLC | $117.1M | 2,516,721 |
| STATE STREET CORP | $114.4M | 2,459,828 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $110.6M | 2,378,329 |
| DIMENSIONAL FUND ADVISORS LP | $96.7M | 2,078,090 |
| GEODE CAPITAL MANAGEMENT, LLC | $73.0M | 1,570,088 |
| Stephens Investment Management Group LLC | $69.1M | 1,485,821 |
Companies Similar to SUPN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Ultragenyx Pharmaceutical Inc.
Evolus, Inc.
NovoCure Ltd
ARDELYX, INC.
Axogen, Inc.
Mirum Pharmaceuticals, Inc.
PTC THERAPEUTICS, INC.
SI-BONE, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SUPN on your watchlist
Track score changes the day SUPERNUS PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SUPN a good stock to buy?
13F Pro's AI-powered analysis of SUPERNUS PHARMACEUTICALS, INC. (SUPN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SUPN are available on the SUPN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SUPN is classified as a mid company.
Which hedge funds own SUPN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SUPN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SUPERNUS PHARMACEUTICALS, INC.'s investment landscape.